Paolo Dambruoso

This inventor holds 10 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 3 EPO patents. Top assignees: Autifony Therapeutics Limited, Autifony Therapeuctics Limited, Glaxo Group Limited. Active years: 2004-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paolo Dambruoso. Retrieved from https://idiyas.com/inventor/paolo-dambruoso

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 1)

% Patents Active = 90.0

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 21(Granted Patents)

Location History:

Putignano, IT (2004)
Verona, IT (2012 - 2023)

Company Filing History:

7 out of 25

Autifony Therapeutics Limited

patents

1 out of 1

Autifony Therapeuctics Limited

Years Active: 2004-2023

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11583527 - Hydantoin derivatives useful as Kv3 inhibitors (2023-02-21),

2. 11197859 - Hydantoin derivatives useful as Kv3 inhibitors (2021-12-14),

3. 11180461 - Triazoles as Kv3 inhibitors (2021-11-23),

4. 10611735 - Triazoles as Kv3 inhibitors (2020-04-07),

5. 10265316 - Hydantoin derivatives useful as Kv3 inhibitors (2019-04-23),

6. 10160730 - Triazoles as KV3 inhibitors (2018-12-25),

7. 9422252 - Triazoles as Kv3 inhibitors (2016-08-23),

8. 9346790 - Hydantoin derivatives useful as Kv3 inhibitors (2016-05-24),

9. 8178549 - Azabicyclo [3. 1. O] hexyl derivatives as modulators of dopamine D3 receptors (2012-05-15),

10. 6768012 - Process for the preparation of paclitaxel (2004-07-27),

Title: Innovator Spotlight: Paolo Dambruoso

Introduction: Paolo Dambruoso, based in Verona, Italy, is a prominent inventor known for his significant contributions to the field of pharmacology and medicinal chemistry. With a notable portfolio of nine patents, Dambruoso has become a notable figure in the pharmaceutical industry. His innovations primarily focus on developing compounds that provide therapeutic benefits, showcasing his commitment to advancing medical science.

Latest Patents: Among his latest innovations, Paolo Dambruoso has developed hydantoin derivatives that serve as Kv3 inhibitors. These compounds are designed to inhibit Kv3 channels and are applicable in the prophylaxis or treatment of related disorders. Such advancements demonstrate not only his inventive spirit but also his dedication to addressing complex health issues through chemical innovation.

Career Highlights: Throughout his career, Paolo Dambruoso has worked with various companies, including Autifony Therapeutics Limited. His experience in this esteemed organization underscores his role in pushing the boundaries of therapeutic development and enhancing treatment options for patients.

Collaborations: Dambruoso has collaborated with talented individuals such as Giuseppe Alvaro and Simona Tommasi. These partnerships have contributed to the successful development of innovative solutions within the pharmaceutical landscape, highlighting the importance of teamwork in scientific progress.

Conclusion: Paolo Dambruoso's contributions to the field of medicinal chemistry through his numerous patents and collaborations reflect his passion and dedication as an inventor. His work continues to influence the pharmaceutical industry, and it will be exciting to see the future innovations that emerge from his ongoing research and development efforts.

Profile summary based on public USPTO records.